New Video Alert: Prescription Drug Discovery Process

New Video Alert: Prescription Drug Discovery Process

03.15.13 | By

The National Institute for Allergy and Infectious Diseases yesterday put out a great new video about the prescription drug discovery process which emphasized the importance of medical innovation partnerships.

As I've said in previous blog posts, partnerships between the government, including federal research institutions, biopharmaceutical research companies and academia are becoming increasingly important to help improve health care for millions of patients suffering from disease.

All three partners have historically depended on one another to combat some of the deadliest diseases facing patients in the U.S. and around the world. The government, for example, is a critical component in advancing medical innovation through the policies and programs it supports. Federal research institutions and academia conduct a lot of basic research and the biopharmaceutical industry often translates that research into the development of life-enhancing medicines.

The prescription drug discovery process is a lengthy and resource-intensive journey - it takes on average $1.3 billion and 10 to 15 years to develop just one medicine. And only 2 of 10 medicines that make it on the market for patients return revenues that match or exceed R&D costs.

Investments made in the research and discovery process are hefty but the incremental gains that have been made to improve patient health are priceless.

My grandmother, for example, celebrated her 83rd birthday on Monday. She is very healthy, walks her dog every day for at least an hour and takes classes at the local university. Fifty years ago, or even 30 years ago this most likely wouldn't have been a realistic scenario.

But with a healthy combination of eating right, exercising and good adherence to prescription medicines, many seniors like my grandmother are living more active and productive lives.

As the most research-intensive and science-driven industry in the U.S., we believe that we are forging an important pathway forward in defeating disease. But in order for us to push the innovation boundaries forward, there needs to be a public policy environment that fosters medical advancements and protects U.S.-based biopharmaceutical jobs.

More On PhRMA — powered by PhRMApedia


Cost in Context